ImQuest CRO HIV Preclinical antiviral anticancer


Our anti-cancer services facilitates the development of novel agents using our cell-based anti-cancer screening program. This platform charcterizes the mechanism of action of new products using cell-based, biochemical, immunologic, and genomic and proteomic based assays. The ImQuest BioSciences' staff has decades of experience with the efficient and cost-effective development of chemotherapeutic agents for the treatment of cancer. Request a quote for Oncology Services.

ImQuest BioSciences performs the following anti-cancer product development services:

Anti-Proliferative Screening Assays

  • Cell-based anti-cancer activity evaluations using the ImQuest BioSciences' OncoSENS platform, which consists of 120 cancer cell lines for the screening of small molecules and biologics
  • Clonogenic assays to complement the anti-proliferative assays, differentiating between cytotoxic and cytostatic modes of action
  • Biochemical and molecular target-based screening assays

Mechanism of Action Evaluations in Cell-based, Immunologic, and Biochemical Assays

  • Direct evaluation of specific inhibitory pathways: cell cycle arrest, apoptosis, kinases, growth factors and signal transduction
  • Resistance selection an characterization of resistant clones
  • Inhibitory pathway validation using binding studies, qPCR, IHC, siRNA, microarrays and flow cytometry
  • Immunophenotyping and cytokine analysis using state-of-the art multi-color flow cytometer, ELISA and cytokine profiling

Evaluation of Combination Anti-Cancer Therapeutic Approaches

  • Statistical analysis of drug combination effects using highly sensitive checkerboard evaluations

Rodent Xenograft and Other In Vivo Models of Compound Efficacy

Evaluation of Off-Target Effects and Safety Profiling

  • Screening for potential toxicity of lead therapeutics in primary cell lines
  • Screening for immune-toxic effects
  • Identification of biomarkers in the preclinical or clinical setting
  • Support for pharmacokinetic/pharmacodynamic studies, and immunogenicity